New Drug Combo Speeds Thinking in Schizophrenia Patients

For decades, doctors have struggled to help the 75% of schizophrenia patients who experience slowed thinking, poor memory, and trouble focusing. Now researchers in Japan have found a treatment combination that actually works.

Scientists at Meijo University discovered that adding a medication called brexpiprazole to patients' existing treatments significantly improved how quickly they could process information. The results appeared within just four weeks and kept getting better over four months.

Professor Hiroyuki Kamei and graduate student Yuma Shimizu studied 19 adults with schizophrenia who were already taking antipsychotic medications but still struggled with thinking clearly. They added brexpiprazole to see if it could help where other treatments fell short.

The researchers used standard cognitive tests to measure processing speed and attention. At every checkpoint (four weeks, eight weeks, and 16 weeks), patients showed meaningful improvement in how fast they could process information.

Why This Inspires

What makes this discovery particularly exciting is that cognitive problems affect people with schizophrenia more than hallucinations or delusions do. These thinking difficulties make it hard to hold jobs, maintain relationships, and participate in daily life. Nearly 80% of patients struggle with unemployment and social isolation because their minds work more slowly than they should.

The improvement happened without making psychiatric symptoms worse, which means patients got clearer thinking without any trade-offs. Their hallucinations and delusions stayed stable while their brains processed information faster.

Even better, the medication worked alongside whatever treatments patients were already taking. Doctors didn't have to switch up entire treatment plans or start from scratch.

"Cognitive impairments in schizophrenia constitute a major barrier to social participation," Professor Kamei explained. His team's work addresses a gap that has frustrated psychiatrists for generations.

The study was small, with just 19 patients, so larger trials are needed to confirm these results. But the preliminary findings give real hope to millions of people worldwide living with schizophrenia who deserve treatments that help them think clearly and live fully.

This research represents more than just another medication trial. It shows that improving quality of life for psychiatric patients is possible when scientists focus on the symptoms that matter most for daily functioning.